Cargando…

L-Mesitran Foam: Evaluation of a New Wound Care Product

Chronic wounds are a health problem that has devastating consequences for patients and their quality of life. Often, chronic wounds are stuck in the inflammatory phase or burdened with an infection. Therefore, it is important to find alternative all-round wound care products that have both wound hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Mthanti, Segametsi Mary-Jane, Pelle, Gloria, Cremers, Niels A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023218/
https://www.ncbi.nlm.nih.gov/pubmed/35464882
http://dx.doi.org/10.1155/2022/4833409
_version_ 1784690291480985600
author Mthanti, Segametsi Mary-Jane
Pelle, Gloria
Cremers, Niels A. J.
author_facet Mthanti, Segametsi Mary-Jane
Pelle, Gloria
Cremers, Niels A. J.
author_sort Mthanti, Segametsi Mary-Jane
collection PubMed
description Chronic wounds are a health problem that has devastating consequences for patients and their quality of life. Often, chronic wounds are stuck in the inflammatory phase or burdened with an infection. Therefore, it is important to find alternative all-round wound care products that have both wound healing and antimicrobial activities. New wound care products are developed constantly, implementing the latest knowledge and advances in wound care. Honey-based wound care formulations and foam dressings are increasingly used in the clinic. L-Mesitran Foam is a novel product in which a foam dressing is precoated with medical-grade honey. Here, we describe our first experiences with L-Mesitran Foam in the clinic. In this case report, a 57-year-old woman with diabetes mellitus type 2 and hypertension presented with a chronic diabetic venous leg ulcer on her leg. Treatments over six months with different treatments, including povidone-iodine, silver dressings, and compression therapy, were ineffective and subsequently switched to L-Mesitran Foam. The dressing choice was based on the wound type and complied with the instructions for use. Wound healing progressed nicely on different aspects and led to complete healing on day 23. No side effects or pain was experienced during treatment. The presented case supports the safety and efficacy of L-Mesitran Foam and serves as a proof of concept.
format Online
Article
Text
id pubmed-9023218
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-90232182022-04-22 L-Mesitran Foam: Evaluation of a New Wound Care Product Mthanti, Segametsi Mary-Jane Pelle, Gloria Cremers, Niels A. J. Case Rep Dermatol Med Case Report Chronic wounds are a health problem that has devastating consequences for patients and their quality of life. Often, chronic wounds are stuck in the inflammatory phase or burdened with an infection. Therefore, it is important to find alternative all-round wound care products that have both wound healing and antimicrobial activities. New wound care products are developed constantly, implementing the latest knowledge and advances in wound care. Honey-based wound care formulations and foam dressings are increasingly used in the clinic. L-Mesitran Foam is a novel product in which a foam dressing is precoated with medical-grade honey. Here, we describe our first experiences with L-Mesitran Foam in the clinic. In this case report, a 57-year-old woman with diabetes mellitus type 2 and hypertension presented with a chronic diabetic venous leg ulcer on her leg. Treatments over six months with different treatments, including povidone-iodine, silver dressings, and compression therapy, were ineffective and subsequently switched to L-Mesitran Foam. The dressing choice was based on the wound type and complied with the instructions for use. Wound healing progressed nicely on different aspects and led to complete healing on day 23. No side effects or pain was experienced during treatment. The presented case supports the safety and efficacy of L-Mesitran Foam and serves as a proof of concept. Hindawi 2022-04-14 /pmc/articles/PMC9023218/ /pubmed/35464882 http://dx.doi.org/10.1155/2022/4833409 Text en Copyright © 2022 Segametsi Mary-Jane Mthanti et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Mthanti, Segametsi Mary-Jane
Pelle, Gloria
Cremers, Niels A. J.
L-Mesitran Foam: Evaluation of a New Wound Care Product
title L-Mesitran Foam: Evaluation of a New Wound Care Product
title_full L-Mesitran Foam: Evaluation of a New Wound Care Product
title_fullStr L-Mesitran Foam: Evaluation of a New Wound Care Product
title_full_unstemmed L-Mesitran Foam: Evaluation of a New Wound Care Product
title_short L-Mesitran Foam: Evaluation of a New Wound Care Product
title_sort l-mesitran foam: evaluation of a new wound care product
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023218/
https://www.ncbi.nlm.nih.gov/pubmed/35464882
http://dx.doi.org/10.1155/2022/4833409
work_keys_str_mv AT mthantisegametsimaryjane lmesitranfoamevaluationofanewwoundcareproduct
AT pellegloria lmesitranfoamevaluationofanewwoundcareproduct
AT cremersnielsaj lmesitranfoamevaluationofanewwoundcareproduct